Lisata Therapeutics reports FY2023 net loss $20.8M; cash $50.5M; ASCEND trial on track for Q4 2024 data

LISATA THERAPEUTICS, INC.

2023-FY EPS reported -$2.58

Net loss of $20.8M for FY2023 vs $54.2M in FY2022; operating expenses $25.7M (down 55% YoY).
Cash, cash equivalents, and marketable securities of $50.5M; runway projected into early 2026.
Phase 2b ASCEND trial in mPDAC fully enrolled; top-line data expected Q4 2024; complete data mid-2025.
R&D expenses $12.7M vs $13.1M prior year; G&A expenses $13.0M vs $14.1M.
Multiple Phase 2a trials ongoing (BOLSTER, CENDIFOX, iLSTA, GBM); Qilu licensee progressing in China.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LISATA THERAPEUTICS, INC. updated its twelve months ended December 31, 2023 guidance (reaffirmed).

Period: twelve months ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.